Cells with characteristics of cancer stem/progenitor cells express the CD133 antigen in human endometrial tumors

Clinical Cancer Research

Volumn 15, Issue 13, 2009, Pages 4299-4311

  Rutella, Sergio ^a,b   Bonanno, Giuseppina ^a,b   Procoli, Annabella ^a   Mariotti, Andrea ^a   Corallo, Maria ^a   Prisco, Maria Grazia ^a   Eramo, Adriana ^c   Napoletano, Chiara ^d   Gallo, Daniela ^a   Perillo, Alessandro ^a   Nuti, Marianna ^d   Pierelli, Luca ^b,d   Testa, Ugo ^c   Scambia, Giovanni ^a   Ferrandina, Gabriella ^a,e  

^a CATHOLIC UNIVERSITY   (Italy)

^b SAN CAMILLO FORLANINI HOSPITAL   (Italy)

^c ISTITUTO SUPERIORE DI SANITÀ   (Italy)

^d SAPIENZA UNIVERSITY OF ROME   (Italy)

^e CATHOLIC UNIVERSITY   (Italy)

Author keywords

[No Author keywords available]

Indexed keywords

CD1 ANTIGEN; CD133 ANTIGEN; CELL MARKER; CHEMOKINE RECEPTOR CXCR4; CISPLATIN; DOXORUBICIN; HERMES ANTIGEN; INTERLEUKIN 8; MATRIX METALLOPROTEINASE; PACLITAXEL; TUMOR ANTIGEN;

ADULT; AGED; ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ANTIGEN EXPRESSION; APOPTOSIS; ARTICLE; CANCER CELL CULTURE; CANCER RESISTANCE; CANCER STEM CELL; CARCINOGENESIS; CELL EXPANSION; CELL ISOLATION; CELL RENEWAL; CELL STRUCTURE; CONTROLLED STUDY; CULTURE MEDIUM; CYTOPATHOGENIC EFFECT; DRUG SENSITIVITY; ENDOMETRIOID CARCINOMA; ENDOMETRIUM CANCER; FEMALE; FLOW CYTOMETRY; GENE EXPRESSION PROFILING; HUMAN; HUMAN CELL; HUMAN TISSUE; IMMUNOHISTOCHEMISTRY; IMMUNOREACTIVITY; MAJOR CLINICAL STUDY; MOUSE; MOUSE STRAIN; NONHUMAN; PHENOTYPE; PRIORITY JOURNAL; REVERSE TRANSCRIPTION POLYMERASE CHAIN REACTION;

ADULT; AGED; AGED, 80 AND OVER; ANIMALS; ANTIGENS, CD; CARCINOMA; ENDOMETRIAL NEOPLASMS; ENDOMETRIUM; FEMALE; GENE EXPRESSION PROFILING; GLYCOPROTEINS; HUMANS; MICE; MICE, INBRED NOD; MICE, SCID; MIDDLE AGED; NEOPLASTIC STEM CELLS; OLIGONUCLEOTIDE ARRAY SEQUENCE ANALYSIS; PEPTIDES; TRANSPLANTATION, HETEROLOGOUS; TUMOR CELLS, CULTURED; TUMOR MARKERS, BIOLOGICAL;

EID: 67650561888     PISSN: 10780432     EISSN: None     Source Type: Journal    
DOI: 10.1158/1078-0432.CCR-08-1883     Document Type: Article

References (57)

1. Sehouli J, Koensgen D, Oskay-Ozcelik G, et al. New aspects of adjuvant therapy in endometrial cancer: current standards and future directions. Crit RevOncol Hematol 2008;67:204-12.
2. Purdie DM, Green AC. Epidemiology of endometrial cancer. Best Pract Res Clin Obstet Gynaecol 2001; 15: 341-54.
3. Morrow CP, Bundy BN, Kurman RJ, et al. Relationship between surgical-pathological risk factors and outcome in clinical stage I and II carcinoma of the endometrium: a Gynecologic Oncology Group study. Gynecol Oncol 1991;40:55-65.
4. Pardal R, Clarke MF,Morrison SJ. Applying the principles of stem-cell biology to cancer. Nat Rev Cancer 2003;3:895-902.
5. Szilvassy SJ, Humphries RK, Lansdorp PM, et al. Quantitative assay for totipotent reconstituting hematopoietic stem cells by a competitive repopulation strategy. ProcNatl Acad SciUSA1990;87:8736-40.
6. Bonnet D, Dick JE. Human acute myeloid leukemia is organized as a hierarchy that originates from a primitive hematopoietic cell. NatMed 1997;3:730-7.
7. Clarke MF. Neurobiology: at the root of brain cancer. Nature 2004;432:281-2.
8. Collins AT, Berry PA, Hyde C, et al. Prospective identification of tumorigenic prostate cancer stem cells. Cancer Res 2005;65:10946-51.
9. Mizrak D, Brittan M, Alison MR. CD133: molecule of the moment. JPathol 2008;214:3-9.
10. Yin AH, Miraglia S, Zanjani ED, et al. AC133, a novel marker for human hematopoietic stem and progenitor cells. Blood1997;90:5002-12.
11. Bonanno G, Perillo A, Rutella S, et al. Clinical isolation and functional characterization of cord blood CD133+ hematopoietic progenitor cells. Transfusion 2004;44:1087-97.
12. Bonanno G,Mariotti A, Procoli A, et al. Human cord blood CD133+ cells immunoselected by a clinicalgrade apparatus differentiate in vitro into endothelialand cardiomyocyte-like cells. Transfusion 2007;47: 280-9.
13. Fargeas CA, Corbeil D, HuttnerWB. AC133 antigen, CD133, prominin-1, prominin-2, etc.: prominin family gene products in need of a rational nomenclature. Stem Cells 2003;21:506-8.
14. Eramo A, Lotti F, Sette G, et al. Identification and expansion of the tumorigenic lung cancer stem cell population. Cell Death Differ 2008;15:504-14.
15. Singh SK, Clarke ID,Terasaki M, et al. Identification of a cancer stem cell in human brain tumors. Cancer Res 2003;63:5821-8.
16. Ferrandina G, Bonanno G, Pierelli L, et al. Expression of CD133-1and CD133-2 in ovarian cancer. Int JGynecol Cancer 2008;18:506-14.
17. Cox CV, Diamanti P, Evely RS, et al. Expression of CD133 on leukemia initiating cells in childhood ALL. Blood 2009;doi:10.1182/blood-2008-04-154187.
18. Ricci-Vitiani L, LombardiDG, Pilozzi E, et al. Identification and expansion of human colon-cancer-initiating cells.Nature 2007;445:111-5.
19. O'Brien CA, Pollett A, Gallinger S, et al. A human colon cancer cell capable of initiating tumour growth in immunodeficient mice. Nature 2007;445: 106 - 10.
20. Ricci-Vitiani L, Pagliuca A, Palio E, et al. Colon cancer stem cells. Gut 2008;57:538-48.
21. Schwab KE, Hutchinson P, Gargett CE. Identification of surfacemarkers for prospective isolation of human endometrial stromal colony-forming cells. Hum Reprod 2008;23:934-43.
22. PhotopulosGJ. Surgicopathologic staging of endometrial adenocarcinoma. Curr Opin Obstet Gynecol 1994;6:92-7.
23. YuY, Flint A, Dvorin EL, et al. AC133-2, a novel isoform of human AC133 stem cell antigen. J Biol Chem 2002;277:20711-6.
24. BabaT, Convery PA,Matsumura N, et al. Epigenetic regulation of CD133 and tumorigenicity of CD133+ ovarian cancer cells. Oncogene 2009;28:209-18.
25. RantanenV, Grenman S, KulmalaJ, et al. Endometrial cancer cell lines are sensitive to paclitaxel. Anticancer Res 1996;16:475-9.
26. Frank NY, Margaryan A, Huang Y, et al. ABCB5-mediated doxorubicin transport and chemoresistance in human malignant melanoma. Cancer Res 2005;65: 4320-33.
27. Steensma DP,Timm M,WitzigTE. Flow cytometric methods for detection and quantification of apoptosis. MethodsMolMed 2003;85:323-32.
28. EramoA, Ricci-Vitiani L, ZeunerA, et al.Chemotherapy resistance of glioblastoma stem cells. Cell Death Differ 2006;13:1238-41.
29. United Kingdom Co-ordinating Committee on Cancer Research (UKCCCR) Guidelines for theWelfare of Animals in Experimental Neoplasia (Second Edition). BrJCancer 1998;77:1-10.
30. RamalingamP,Malpica A, Silva EG, et al.The use of cytokeratin 7 and EMA in differentiating ovarian yolk sac tumors from endometrioid and clear cell carcinomas. AmJ Surg Pathol 2004;28:1499-505.
31. Green CL, Loken M, Buck D, et al. Discordant expression of AC133 and AC141 in patients with myelodysplastic syndrome (MDS) andacutemyelogeneous leukemia (AML). Leukemia 2000;14:770-2.
32. Rutella S, Bonanno G, Marone M, et al. Identification of a novel subpopulation of human cord blood CD34-133-CD7-45+lineagePcells capable of lymphoid/ NK cell differentiation after in vitro exposure to IL-15. J Immunol 2003;171:2977-88.
33. Engelmann K, Shen H, Finn OJ.MCF7 side population cells with characteristics of cancer stem/progenitor cells express the tumor antigenMUC1. Cancer Res 2008;68:2419-26.
34. Pierelli L, Marone M, Bonanno G, et al. Modulation of bcl-2 and p27 in human primitive proliferating hematopoietic progenitors by autocrine TGF-b1is a cell cycle-independent effect and influences their hematopoietic potential. Blood 2000;95:3001-9.
35. Rutella S, Pierelli L, Bonanno G, et al. Homogeneous expression of CXC chemokine receptor 4 (CXCR4) on G-CSF-mobilized peripheral blood CD34+ cells. Blood 2000;95:4015-6.
36. Manfredini R, Zini R, Salati S, et al. The kinetic status of hematopoietic stem cell subpopulations underlies a differential expression of genes involved in self-renewal, commitment, and engraftment. Stem Cells 2005;23:496-506.
37. Al-HajjM,WichaMS,Benito-HernandezA, etal.Prospective identification of tumorigenic breast cancer cells. ProcNatl Acad SciUSA 2003;100:3983-8.
38. Du L,Wang H, He L, et al. CD44 is of functional importance for colorectal cancer stem cells. Clin Cancer Res 2008;14:6751-60.
39. MikiJ, Furusato B, Li H, et al. Identification of putative stem cell markers, CD133 and CXCR4, in hTERTimmortalized primary nonmalignant and malignant tumor-derived human prostate epithelial cell lines and in prostate cancer specimens. Cancer Res 2007;67: 3153-61.
40. Kucia M, Reca R, Miekus K, et al. Trafficking of normal stem cells and metastasis of cancer stem cells involve similar mechanisms: pivotal role of the SDF-1-CXCR4 axis. Stem Cells 2005;23:879-94.
41. Lapidot T, Sirard C,Vormoor J, et al. A cell initiating human acute myeloid leukaemia after transplantation into SCIDmice. Nature1994;367:645-8.
42. Jordan CT, Guzman ML, Noble M. Cancer stem cells. NEngl JMed 2006;355:1253-61.
43. Jamieson CH, Ailles LE, Dylla SJ, et al. Granulocyte-macrophage progenitors as candidate leukemic stem cells in blast-crisis CML. N Engl JMed 2004; 351:657-67.
44. Ma S, LeeTK, Zheng BJ, et al. CD133+ HCC cancer stem cells confer chemoresistance by preferential expression of the Akt/PKB survival pathway. Oncogene 2008;27:1749-58.
45. Zhang S, Balch C, Chan MW, et al. Identification and characterization of ovarian cancer-initiating cells from primary human tumors. Cancer Res 2008;68: 4311-20.
46. Clarke MF, Dick JE, Dirks PB, et al. Cancer stem cells-perspectives on current status and future directions: AACR Workshop on cancer stem cells. Cancer Res 2006;66:9339-44.
47. Collins AT, Habib FK, Maitland NJ, et al. Identification and isolation of human prostate epithelial stem cells based on a2b1-integrin expression. J Cell Sci 2001;114:3865-72.
48. Kalirai H, Clarke RB. Human breast epithelial stem cells and their regulation. JPathol 2006;208:7-16.
49. Dontu G, El-Ashry D,Wicha MS. Breast cancer, stem/progenitor cells and the estrogen receptor. Trends EndocrinolMetab 2004;15:193-7.
50. Napoletano C, Rughetti A, AgervigTarp MP, et al. Tumor-associated Tn-MUC1glycoform is internalized through the macrophage galactose-type C-type lectin and delivered to the HLA class I and II compartments in dendritic cells. Cancer Res 2007;67:8358-67.
51. VisvaderJE, Lindeman GJ. Cancer stem cells in solid tumours: accumulating evidence and unresolved questions. Nat Rev Cancer 2008;8:755-68.
52. Shmelkov SV, Butler JM, Hooper AT, et al. CD133 expression is not restricted to stem cells, and both CD133+ and CD133- metastatic colon cancer cells initiate tumors. JClin Invest 2008;118:2111-20.
53. Joo KM, Kim SY, Jin X, et al. Clinical and biological implications of CD133-positive and CD133-negative cells in glioblastomas. Lab Invest 2008;88:808-15.
54. Wang J, Sakariassen PO, Tsinkalovsky O, et al. CD133 negative glioma cells form tumors in nude rats and give rise to CD133 positive cells. Int J Cancer 2008;122:761-8.
55. Kusumbe AP, Mali AM, Bapat SA. CD133-expressing stem cells associated with ovarian metastases establish an endothelial hierarchy and contribute to tumor vasculature. Stem Cells 2009;27:498-508.
56. LaBarge MA, Bissell MJ. Is CD133 a marker of metastatic colon cancer stem cells ? J Clin Invest 2008;118:2021-4.
57. Al-Hajj M. Cancer stem cells and oncology therapeutics. Curr Opin Oncol 2007;19:61-4.